Sensius provides a precision thermotherapy platform that delivers focused microwave heating to deep‑seated head and neck tumors, raising the temperature to about 42 °C to boost the effectiveness of radiotherapy, chemotherapy, and immunotherapy. The patented system integrates real‑time temperature monitoring and safety controls into existing radiotherapy workflows, enabling clinicians to improve tumor control while reducing toxicity and treatment costs.
Funding
$7.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with head and neck cancer often receive radiotherapy, chemotherapy, or immunotherapy that can cause significant toxicity and limited tumor control, leading to reduced quality of life and higher treatment costs. Adding a controlled heat boost to the tumor can enhance the effectiveness of these therapies, but existing hyperthermia devices are bulky, imprecise, and difficult to integrate into standard radiotherapy workflows.
Solution
Sensiusthermotherapy offers a precision thermotherapy platform that delivers focused microwave heating to deep‑seated head and neck tumors while preserving surrounding healthy tissue. The system is designed to align with existing radiotherapy procedures, allowing clinicians to apply a mild‑heat boost (≈42 °C) directly to the tumor site during a treatment session. By raising tumor temperature, the platform amplifies the biological response to radiation and systemic therapies, improving tumor control and reducing side‑effects. Patented hardware provides high spatial focus and real‑time temperature monitoring, ensuring safe and reproducible heating. Clinical prototypes are already being evaluated in a Phase I trial at Erasmus MC, demonstrating feasibility and early efficacy signals. The technology aims to become a standard adjunct that balances treatment efficacy with patient quality of life.
Target Audience
Primary customers are radiation oncology departments and head‑and‑neck cancer treatment centers seeking to enhance therapeutic outcomes while minimizing toxicity.
Features
- Patented microwave applicator (Focuscore) that concentrates energy on the tumor with millimeter precision
- Integrated temperature sensors and feedback control to maintain target temperature (≈42 °C) throughout the session
- Seamless workflow integration with conventional radiotherapy equipment and treatment planning systems
- Automated safety checks and dose monitoring to protect adjacent organs at risk
- Scalable hardware platform designed for use in hospital radiotherapy suites
- Clinical validation program including Phase I trials and collaborations with leading oncology centers